Standard Yervoy Dosing Protocol
Yervoy (ipilimumab), a Bristol Myers Squibb immunotherapy for melanoma and other cancers, follows fixed dosing schedules without personalization based on individual patient factors like weight, age, or genetics. The standard adult dose is 3 mg/kg intravenously every 3 weeks for four doses, followed by maintenance if combined with Opdivo (nivolumab), or 1 mg/kg every 6 weeks in some regimens.[1][2]
When Do Doctors Adjust Dosage?
Adjustments occur only for toxicity management, not personalization. Hold or discontinue based on immune-related adverse events (irAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE):
- Grade 2: Hold until recovery to Grade 0 or 1.
- Grade 3: Hold and resume at reduced dose (e.g., from 3 mg/kg to 1 mg/kg) after recovery.
- Grade 4 or persistent: Permanently discontinue.
No routine adjustments for renal/hepatic impairment unless severe; pediatric dosing scales by body weight (e.g., 10 mg/kg in some trials).[1][3]
Factors Not Used for Personalization
- Body weight/size: Fixed mg/kg, unlike some chemotherapies.
- Genetics/PD-L1 status: No biomarkers guide dosing (differs from Keytruda, where expression influences selection).
- Comorbidities: Standard unless toxicity arises; elderly patients follow adult dosing.[2]
How This Compares to Other Immunotherapies
| Drug | Dosing Style | Personalization? |
|------|--------------|------------------|
| Yervoy | Fixed mg/kg | Toxicity only |
| Keytruda (pembrolizumab) | Flat 200-400 mg or 2 mg/kg | PD-L1 for some indications |
| Opdivo (nivolumab) | Flat 240-480 mg | Weight-based options in combos |
| Tecentriq (atezolizumab) | Flat 1680 mg | None routine |
Yervoy's approach prioritizes simplicity in trials like CheckMate studies, where fixed doses showed consistent efficacy.[3]
Patient Concerns on Dosing Variations
Patients report confusion over combo regimens (e.g., Yervoy + Opdivo at 1 mg/kg + 3 mg/kg), but no tailoring for body surface area or ethnicity. Real-world data from registries like Flatiron Health show ~20-30% require holds for irAEs, mimicking trial adjustments.[4]
[1]: Yervoy Prescribing Information (BMS, 2023)
[2]: FDA Label for Ipilimumab
[3]: CheckMate-067 Trial (NEJM, 2015; updated 2023)
[4]: Flatiron Health Analysis on ICI Dosing (JCO, 2022)